- No public price. The site shows no plan, billing period or trial.
- Not disclosed
- Not disclosed
- —
- —
- FR

AZmed Rayvolve
by AZmed · FR
Rayvolve AI suite: fracture detection on X-ray, chest X-ray findings, lymph node and CT lung nodule detection.
On this page
- Regulatory & Compliance18/28
FDA cleared (6 K-numbers on record)
- Clinical Integration0/26
No EHR integrations listed
- Evidence Strength0/26
No peer-reviewed coverage
- Vendor & Market3/18
Seed-stage or unfunded
- Sentiment & Transparency2.5/14
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance18/18
FDA cleared (6 K-numbers on record)
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/14
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/8
None of the top-3 EHRs covered
- Bidirectional write-back0/4
No bidirectional write-back documented
- Peer-reviewed papers0/18
No peer-reviewed coverage
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal3/12
Seed-stage or unfunded
- Years in market0/6
Founded year not recorded
- Clinician sentiment (Reddit)0/9
No clinician sentiment data available
- Pricing transparency3/5
Pricing on request, no public amounts
Rayvolve AI suite: fracture detection on X-ray, chest X-ray findings, lymph node and CT lung nodule detection.
No public price. The site shows no plan, billing period or trial.
Bottom line
Rayvolve is a radiology AI suite from AZmed of Paris. It began as fracture detection on standard X-rays and now also covers chest X-ray findings, a lymph node module and CT lung nodules. The FDA's 510(k) records list six clearances between June 2022 and August 2026. Price is by quote. It suits a radiology department or imaging network with high plain-film volume.
What is in the Rayvolve suite?
AZmed's site title reads "AI Radiology: Fracture Detection, Chest, Measure, BoneAge", and the product list follows it:
- Rayvolve for fracture detection on X-ray, the flagship
- AZchest for lung nodule detection, with pneumothorax and pleural effusion triage
- Rayvolve LN, a lymph node module
- AZnod for lung nodule detection on CT
- bone age assessment
- RIS-integrated report prefill, launched on 2 October 2025 according to AZmed's announcement
AZmed says more than 2,500 healthcare facilities use its products worldwide, and LeadIQ lists 55 countries.
What has the FDA cleared?
The 510(k) records list six clearances under AZmed:
- K220164, June 2022, Rayvolve (applicant listed as Azmed Sas)
- K240845, July 2024, Rayvolve
- K243808, March 2025, Rayvolve PTX-PE
- K243831, March 2025, Rayvolve LN
- K260378, May 2026, Rayvolve
- K261378, August 2026, Rayvolve AZchest
That is six clearances in four years. AZmed's site says it has eight FDA-cleared findings. Rayvolve PTX-PE, LN and AZchest each appear under their own K-number, and none of the six carries the AZnod name.
Who is the company?
AZmed is a Paris company. It announced a EUR 15 million Series A on 20 February 2024, with investors including Maison Worms, Techstars and Teampact Ventures. Tracxn totals its funding at $21.5 million over three rounds.
How is Rayvolve priced?
AZmed publishes no price. Licences are quoted on request.
The verdict
A radiology department or outpatient imaging network reading many plain films is the natural buyer for Rayvolve, and the suite's report prefill connects to a RIS. A US site that wants CT lung nodule detection from AZnod has no 510(k) under that name to point to.
Editorial review last generated October 15, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Quote only | — | — | No public price. The site shows no plan, billing period or trial. |
Source: vendor pricing page. Last checked October 15, 2026.
What deploys cleanly
Carries FDA 510(k) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.




